Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD

Background and ObjectiveNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) are autoimmune inflammatory demyelinating diseases of the central nervous system (CNS). As the clinical features of NMOSD are similar to MOGAD...

Full description

Bibliographic Details
Main Authors: Liuyu Lin, Yuqing Wu, Hailun Hang, Jie Lu, Yuanliang Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
neuromyelitis optica spectrum disorder
myelin oligodendrocyte glycoprotein antibody-associated disease
complement 3
complement 4
blood brain barrier (BBB)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.853891/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.853891/full

Similar Items